EC Number   |
Application |
Reference |
|---|
    2.7.1.48 | biotechnology |
overexpression of gene udk encoding uridine/cytidine kinase interferes with T7 bacteriophage growth. This inhibition can be overcome by inhibition of host RNA polymerase by overexpression of gene 2 or by treatment with rifampicin. General model for the requirement of host RNA polymerase inhibition |
694223 |
| 2.7.1.48 | diagnostics |
increased UCK2 expression is an independent prognostic indicator of shorter overall survival and recurrence-free survival. UCK2 upregulation might serve as an indicator of unfavorable prognosis of hepatocellular carcinoma |
761333 |
| 2.7.1.48 | diagnostics |
prognostic significance of UCK2 gene in patients with breast cancer. UCK2 is required for chexadmosensitivity |
759533 |
| 2.7.1.48 | drug development |
RX-3117, an orally available cytidine analogue, is activated by UCK2 which may be used to select patients potentially sensitive to RX-3117 |
760017 |
| 2.7.1.48 | medicine |
liver-specific targeting of ribavirin by conjugation with asialoglycoprotein to enhance its antiviral activity. Conjugation reaction starts with ribavirin phosphorylation by uridine kinase followed by direct conjugation to asioloosomucoid |
693270 |
| 2.7.1.48 | medicine |
role of UCK2-dependant nucleoside analogues in cancer therapy, overview. Nucleoside antimetabolites are amongst the most important chemotherapeutic agents currently used or under clinical trials against several cancers. This included the important clinically used nucleoside analogue, 5-fluorouracil. UCK2 is also involved in the phosphorylation of ribonucleoside analogues, 5-azacytidine, cyclopentenyl cytosine/uracil, 5-fluorocytidine, 6-azauridine, 3-deazauridine, 5-fluorouridine as well as ethynyl cytidine and uridine. To exert their pharmacological actions, these cytotoxic drugs depend on the action of the UCK2 enzyme to sequentially transform them into nucleoside 5'-triphosphate, thereby interfering with gene synthesis vital for metabolic processes required for cancer cell growth and maintenance |
758880 |
| 2.7.1.48 | medicine |
target for antitumor and antiviral drug design |
660609, 663411 |
